Friedemann Paul , Yang Mao-Draayer , Dean Wingerchuk , Jennifer Graves , Amy Kunchok , Elijah A. Lackey , Kazuo Fujihara , Douglas K. Sato , Dan Cimbora , Kristina R. Patterson , Bruce Cree
{"title":"Inebilizumab在50岁及以上视神经脊髓炎谱系障碍患者中的疗效和安全性:n -动量研究亚组分析","authors":"Friedemann Paul , Yang Mao-Draayer , Dean Wingerchuk , Jennifer Graves , Amy Kunchok , Elijah A. Lackey , Kazuo Fujihara , Douglas K. Sato , Dan Cimbora , Kristina R. Patterson , Bruce Cree","doi":"10.1016/j.clinph.2025.2110831","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10671,"journal":{"name":"Clinical Neurophysiology","volume":"176 ","pages":"Article 2110831"},"PeriodicalIF":3.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of Inebilizumab in patients 50 years of age and older with neuromyelitis optica spectrum disorder: N-MOmentum study subgroup analysis\",\"authors\":\"Friedemann Paul , Yang Mao-Draayer , Dean Wingerchuk , Jennifer Graves , Amy Kunchok , Elijah A. Lackey , Kazuo Fujihara , Douglas K. Sato , Dan Cimbora , Kristina R. Patterson , Bruce Cree\",\"doi\":\"10.1016/j.clinph.2025.2110831\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10671,\"journal\":{\"name\":\"Clinical Neurophysiology\",\"volume\":\"176 \",\"pages\":\"Article 2110831\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neurophysiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1388245725006832\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurophysiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1388245725006832","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Efficacy and safety of Inebilizumab in patients 50 years of age and older with neuromyelitis optica spectrum disorder: N-MOmentum study subgroup analysis
期刊介绍:
As of January 1999, The journal Electroencephalography and Clinical Neurophysiology, and its two sections Electromyography and Motor Control and Evoked Potentials have amalgamated to become this journal - Clinical Neurophysiology.
Clinical Neurophysiology is the official journal of the International Federation of Clinical Neurophysiology, the Brazilian Society of Clinical Neurophysiology, the Czech Society of Clinical Neurophysiology, the Italian Clinical Neurophysiology Society and the International Society of Intraoperative Neurophysiology.The journal is dedicated to fostering research and disseminating information on all aspects of both normal and abnormal functioning of the nervous system. The key aim of the publication is to disseminate scholarly reports on the pathophysiology underlying diseases of the central and peripheral nervous system of human patients. Clinical trials that use neurophysiological measures to document change are encouraged, as are manuscripts reporting data on integrated neuroimaging of central nervous function including, but not limited to, functional MRI, MEG, EEG, PET and other neuroimaging modalities.